Kunbo Yu
Research Subjects
Research Interests
Kunbo Yu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- James Li
Myriad Neuroscience
2 shared publications - Julie-Anne Tanner
Myriad Neuroscience
2 shared publications Allan Anderson
Banner Health
1 shared publicationBryan M Dechairo
Myriad Genetics, Inc., Salt Lake City, UT, USA
1 shared publication- David S. Geldmacher
Department of Neurology, Marnix E. Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL
1 shared publication - Giovanna Pilonieta
Heersink School of Medicine, University of Alabama at Birmingham
1 shared publication
Latest Publications
- Open Access
- 1 December 2019
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 11, 779-787
Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications
Objective: To estimate Canadian pharmacy cost savings associated with psychiatric medication prescribing that is guided by combinatorial pharmacogenomic testing in patients switching or augmenting their psychiatric medication. Methods: Pharmacy claims data from a United States (US) pharmacy benefit manager were analyzed for 1662 patients who recently augmented or switched to a different antidepressant or antipsychotic medication and underwent combinatorial pharmacogenomic testing. Costs of prescription medications were translated to the Canadian healthcare system by matching drug names and doses using the Ontario Drug Benefit Formulary. One-year costs (2017 CAD) were compared between patients whose clinician prescribed antidepressants or antipsychotics that were consistent (congruent) or inconsistent (incongruent) with the combinatorial pharmacogenomic test recommendations. Results: Patients whose psychiatric medication treatment was congruent with the combinatorial pharmacogenomic test report saved $1061 CAD per member per year (PMPY) on prescription medication costs relative to patients whose medications were incongruent with their test report (pConclusions: Antidepressant and antipsychotic prescribing that was congruent with combinatorial pharmacogenomic test guidance was associated with significant cost savings on Canadian prescription medications according to the Ontario Drug Benefit Formulary.
- 1 December 2019
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 11, 779-787
Open AccessCanadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications
Objective: To estimate Canadian pharmacy cost savings associated with psychiatric medication prescribing that is guided by combinatorial pharmacogenomic testing in patients switching or augmenting their psychiatric medication. Methods: Pharmacy claims data from a United States (US) pharmacy benefit manager were analyzed for 1662 patients who recently augmented or switched to a different antidepressant or antipsychotic medication and underwent combinatorial pharmacogenomic testing. Costs of prescription medications were translated to the Canadian healthcare system by matching drug names and doses using the Ontario Drug Benefit Formulary. One-year costs (2017 CAD) were compared between patients whose clinician prescribed antidepressants or antipsychotics that were consistent (congruent) or inconsistent (incongruent) with the combinatorial pharmacogenomic test recommendations. Results: Patients whose psychiatric medication treatment was congruent with the combinatorial pharmacogenomic test report saved $1061 CAD per member per year (PMPY) on prescription medication costs relative to patients whose medications were incongruent with their test report (pConclusions: Antidepressant and antipsychotic prescribing that was congruent with combinatorial pharmacogenomic test guidance was associated with significant cost savings on Canadian prescription medications according to the Ontario Drug Benefit Formulary.